Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Non-randomized Multicentric Phase 2 Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2-T4a or N+ Gastric and GEJ Adenocarcinoma Overexpressing FGFR2b

NCT06967987 is registered in ClinicalTrials.gov with Institut Cancerologie de l'Ouest as lead sponsor.

NCT NCT06967987
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06967987 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Non-randomized Multicentric Phase 2 Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2-T4a or N+ Gastric and GEJ Adenocarcinoma Overexpressing FGFR2b
Lead sponsor
Institut Cancerologie de l'Ouest
Phase
Phase 2
Overall status
Withdrawn
Start date
January 1, 2026
Completion date
January 1, 2026
Enrollment
0 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

gastric and gastro-oesophageal junction (gej) adenocarcinomas, overexpression fgfr2b